Mechanistic Target of Rapamycin (serine/threonine Kinase) (FRAP1) (AA 185-290) antibody
|Synonyms||FRAP, FRAP1, FRAP2, RAFT1, RAPT1, FLJ44809, flat, Frap1, AI327068, MGC118056, 2610315D21Rik, tor, fc22h08, wu:fc22h08, MTOR, TOR, RORG, RZRG, NR1F3, MGC129539, RZR-GAMMA|
Alternatives Western Blotting (WB), Immunofluorescence (IF)
|5 references available|
|Quantity||150 µg (250 µg/ml) (Variants)|
|Price||Product not available in this region.|
|Cross-Reactivity||Human, Mouse (Murine), Chicken|
Immunosuppressive agents such as cyclosporin A, FK506, and rapamycin are used routinely in clinical transplantation and the treatment of autoimmune disorders. Cyclosporin A and FK506 bind to cyclophilins and the FK-binding protein FKBP12, respectively. These complexes interact with, and inhibit the activity of, the calcineurin protein phosphatase, which is essential for T cell activation. Rapamycin also interacts with FKBP12, but this complex does not affect calcineurin. Instead, it inhibits signals required for G1 to S progression in yeast, in IL-2-stimulated T lymphocytes, and other mammalian cell types. Rapamycin-FKBP12 binds to a protein designated Rapamycin And FKBP12 Target-1 (RAFT1) in rats and FKBP-Rapamycin-Associated Protein (FRAP) in humans. RAFT1 is the homolog of the yeast genes TOR1 and TOR2 which, when mutated, lead to rapamycin resistance. RAFT1 is a PI4-kinase that exhibits homology with other PI kinases such as PI3-kinase and PI4-Kalpha. RAFT1 phosphorylates p70 S6 kinase and 4E-BP1 which are regulators of translational initiation. However, rapamycin-FKBP1 does not inhibit PI4-kinase activity and, therefore, affects RAFT1 activity via alternate mechanisms.
Synonyms: Rapamycin And FKBP12 Target-1
1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
|Molecular Weight||245 kDa|
Related Products: ABIN967389, ABIN968539
|Purification||Purified from tissue culture supernatant or ascites by affinity chromatography.|
|Buffer||Aqueous buffered solution containing BSA, glycerol.|
|Preservative||0.09% Sodium azide.|
|Storage||Store undiluted at -20° C.|
|Restrictions||For Research Use only|
Sabatini, Erdjument-Bromage, Lui et al.: "RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs." in: Cell, Vol. 78, Issue 1, pp. 35-43, 1994 (PubMed).
Sabatini, Pierchala, Barrow et al.: "The rapamycin and FKBP12 target (RAFT) displays phosphatidylinositol 4-kinase activity." in: The Journal of biological chemistry, Vol. 270, Issue 36, pp. 20875-8, 1995 (PubMed).
Alarcon, Cardenas, Heitman: "Mammalian RAFT1 kinase domain provides rapamycin-sensitive TOR function in yeast." in: Genes & development, Vol. 10, Issue 3, pp. 279-88, 1996 (PubMed).
Burnett, Barrow, Cohen et al.: "RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, Issue 4, pp. 1432-7, 1998 (PubMed).
Castedo, Ferri, Blanco et al.: "Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-associated protein-mediated p53 phosphorylation." in: The Journal of experimental medicine, Vol. 194, Issue 8, pp. 1097-110, 2001 (PubMed).